Connote Healthcare Private Limited

The Pioglitazone Hydrochloride 15 mg + Metformin Hydrochloride (ER) 850 mg Tablet is a dual-combination oral medication designed for the comprehensive management of Type 2 Diabetes Mellitus in adults. This tablet is typically prescribed when blood sugar levels are not adequately controlled by diet, exercise, and monotherapy with either pioglitazone or metformin, or when patients are already stable on both components taken separately. This formulation combines two potent antidiabetic agents with distinct mechanisms of action:

1. Pioglitazone (Thiazolidinedione - TZD): This component works as an insulin sensitizer. It activates Peroxisome Proliferator-Activated Receptor gamma (PPARγ), a nuclear receptor found in tissues crucial for insulin action (like fat, muscle, and liver). Activation of PPARγ leads to:

   • Increased Insulin Sensitivity: Cells become more responsive to insulin, enhancing glucose uptake and utilization by peripheral tissues.
   • Reduced Hepatic Glucose Output: Decreases the amount of glucose produced and released by the liver. Pioglitazone's action is dependent on the presence of insulin, but it does not directly stimulate insulin secretion, thus having a low risk of hypoglycemia when used alone.

2. Metformin Hydrochloride (Biguanide) - Extended Release (ER): The Metformin component acts by:

   • Reducing Hepatic Glucose Production: It significantly decreases the amount of glucose produced and released by the liver.
   • Decreasing Intestinal Glucose Absorption: It slows down the absorption of sugar from the foods consumed in the intestines.
   • Increasing Insulin Sensitivity: It further improves the body's response to its own insulin, allowing cells to utilize glucose more efficiently. The Extended Release (ER) formulation ensures a gradual and prolonged release of metformin, providing more consistent blood sugar control over 24 hours and often improving gastrointestinal tolerability compared to immediate-release forms.

This combination offers a robust approach to diabetes management by tackling both insulin resistance and excessive glucose production, addressing key pathophysiological defects in Type 2 Diabetes.

Key Features:

• Dual-Action Formula: Combines an insulin sensitizer (Pioglitazone) with an insulin sensitizer/glucose production reducer (Metformin) for synergistic effects.
• Comprehensive Glycemic Control: Effectively lowers both fasting and post-meal blood sugar levels.
• Addresses Insulin Resistance: Directly targets a root cause of Type 2 Diabetes.
• Extended Release Metformin: Provides prolonged action and often reduces common GI side effects.
• Convenient Dosing: Fixed-dose combination in a single ER tablet simplifies the medication regimen.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Pioglitazone Hydrochloride IP equivalent to Pioglitazone: 30 mg
• Metformin Hydrochloride IP: 500 mg (as Extended Release)
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients whose blood glucose levels are not adequately controlled with either metformin or pioglitazone monotherapy, or who are already being treated with both medications separately.

Glimepiride 1 mg + Metformin HCl 500 mg Tablet is a widely used dual-combination oral medication for the effective management of Type 2 Diabetes Mellitus in adults. It is typically prescribed when diet, exercise, and monotherapy with either glimepiride or metformin alone do not adequately control blood sugar levels. This tablet combines two distinct classes of antidiabetic agents to provide a synergistic effect:

1. Glimepiride (Sulfonylurea): This component primarily acts by stimulating the beta cells in the pancreas to release more insulin. This increase in insulin helps to lower blood glucose by facilitating its uptake into cells and reducing glucose production by the liver.
2. Metformin Hydrochloride (Biguanide): This component works through several mechanisms:
   • Reduces Hepatic Glucose Production: It decreases the amount of glucose produced and released by the liver.
   • Decreases Intestinal Glucose Absorption: It slows down the absorption of sugar from the foods consumed in the intestines.
   • Increases Insulin Sensitivity: It enhances the body's response to its own insulin, making cells more efficient at absorbing and utilizing glucose.

By combining these two agents, the tablet offers a comprehensive approach to managing Type 2 Diabetes by addressing both insulin deficiency and insulin resistance, leading to improved glycemic control. The Metformin component is often in a Sustained Release (SR) or Prolonged Release (PR) form, providing a gradual release for consistent blood sugar control throughout the day and often improved gastrointestinal tolerability.

Key Features:

• Dual-Action Formula: Combines an insulin secretagogue (Glimepiride) and an insulin sensitizer/glucose production reducer (Metformin) for enhanced efficacy.
• Comprehensive Glycemic Control: Effectively lowers both fasting and post-meal blood sugar levels.
• Convenient Dosing: Fixed-dose combination simplifies the medication regimen for patients.
• Improved Insulin Utilization: Metformin helps the body use its own insulin more effectively.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Glimepiride 4 mg tablets are an oral antidiabetic medication belonging to the sulfonylurea class. It is used for the management of Type 2 Diabetes Mellitus in adults. This lower strength is particularly useful for initiating therapy, for patients requiring a milder dose to achieve glycemic control, or as part of a combination regimen.

 

Mechanism of Action: Glimepiride primarily works by stimulating the beta cells in the pancreas to release more insulin. It achieves this by binding to specific receptors on these cells, which leads to the closure of ATP-sensitive potassium channels. This triggers a cascade of events that cause the pancreatic beta cells to depolarize and release insulin. The increased insulin in the bloodstream helps to lower blood glucose by facilitating glucose uptake into cells and reducing hepatic glucose output. Glimepiride also exhibits some extrapancreatic effects, potentially improving insulin sensitivity.

 

Key Features:

• Insulin Secretagogue: Directly stimulates the pancreas to increase insulin secretion.
• Effective Blood Glucose Control: Helps lower both fasting and post-meal blood sugar levels.
• Flexible Dosing: Available in various strengths, allowing for dose titration based on individual patient needs.
• Once-Daily Dosing: Can be taken once daily with breakfast or the first main meal.
• Quality Assured: Manufactured in WHO-GMP certified facilities.

Composition (per tablet):

• Glimepiride IP: 0.5 mg
• Excipients: q.s.

Indications:

• Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise in adult patients to improve glycemic control. It can be used as monotherapy (especially in newly diagnosed patients or those sensitive to higher doses) or in combination with other oral antidiabetic agents (e.g., Metformin) or insulin.

Prolonged Release Metformin Tablets 1000 mg represent an advanced formulation of a cornerstone medication in the management of type 2 diabetes mellitus. Designed for extended action, each tablet contains 1000 milligrams of metformin hydrochloride, a biguanide oral antihyperglycemic agent. This prolonged-release (PR) or extended-release (ER) formulation is engineered to release metformin gradually over an extended period, ensuring more stable blood glucose levels throughout the day and night while potentially improving gastrointestinal tolerability compared to immediate-release formulations. It is primarily indicated for adults with type 2 diabetes, especially those who are overweight or obese, where diet and exercise alone have not achieved adequate glycemic control. Metformin works through multiple mechanisms, including reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by enhancing peripheral glucose uptake and utilization. This multifaceted action helps to lower both basal and postprandial plasma glucose levels without stimulating insulin secretion, thereby minimizing the risk of hypoglycemia when used as monotherapy.

The sustained-release profile of Metformin PR 1000 mg allows for convenient once-daily dosing, typically taken with the evening meal to optimize its therapeutic effects overnight. This regimen can significantly enhance patient adherence and reduce the fluctuation of metformin levels in the bloodstream. For adults, the usual starting dose of prolonged-release metformin is often 500 mg once daily, which may be gradually titrated up to 1000 mg, or even higher doses (up to a maximum of 2000 mg once daily), based on individual glycemic response and tolerability, as directed by a healthcare professional. Tablets should be swallowed whole and not crushed, chewed, or broken, as this would compromise the prolonged-release mechanism.

Prolonged Release Metformin Tablets 500 mg represent an advanced formulation of a cornerstone medication in the management of type 2 diabetes mellitus. Designed for extended action, each tablet contains 1000 milligrams of metformin hydrochloride, a biguanide oral antihyperglycemic agent. This prolonged-release (PR) or extended-release (ER) formulation is engineered to release metformin gradually over an extended period, ensuring more stable blood glucose levels throughout the day and night while potentially improving gastrointestinal tolerability compared to immediate-release formulations. It is primarily indicated for adults with type 2 diabetes, especially those who are overweight or obese, where diet and exercise alone have not achieved adequate glycemic control. Metformin works through multiple mechanisms, including reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by enhancing peripheral glucose uptake and utilization. This multifaceted action helps to lower both basal and postprandial plasma glucose levels without stimulating insulin secretion, thereby minimizing the risk of hypoglycemia when used as monotherapy.

The sustained-release profile of Metformin PR 1000 mg allows for convenient once-daily dosing, typically taken with the evening meal to optimize its therapeutic effects overnight. This regimen can significantly enhance patient adherence and reduce the fluctuation of metformin levels in the bloodstream. For adults, the usual starting dose of prolonged-release metformin is often 500 mg once daily, which may be gradually titrated up to 1000 mg, or even higher doses (up to a maximum of 2000 mg once daily), based on individual glycemic response and tolerability, as directed by a healthcare professional. Tablets should be swallowed whole and not crushed, chewed, or broken, as this would compromise the prolonged-release mechanism.